Literature DB >> 8482955

Patterns of blood-brain barrier impairment and clinical features in multiple sclerosis.

B N McLean1, A Z Zeman, D Barnes, E J Thompson.   

Abstract

Seventy four patients with clinically definite multiple sclerosis were studied by using polyacrylamide gel electrophoresis of cerebrospinal fluid to assess blood-brain barrier function. Blood-brain barrier impairment was associated with recent clinical relapses of multiple sclerosis and worsened across a spectrum from the relapsing-remitting type of multiple sclerosis to secondary and primary progressive disease. The association between blood-brain barrier impairment and primary progressive disease is particularly interesting in the light of recent evidence that focal gadolinium enhancement on MRI is relatively unusual in patients with this disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482955      PMCID: PMC1014950          DOI: 10.1136/jnnp.56.4.356

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  26 in total

1.  Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications.

Authors:  A G Kermode; A J Thompson; P Tofts; D G MacManus; B E Kendall; D P Kingsley; I F Moseley; P Rudge; W I McDonald
Journal:  Brain       Date:  1990-10       Impact factor: 13.501

2.  Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study.

Authors:  D Gay; M Esiri
Journal:  Brain       Date:  1991-02       Impact factor: 13.501

3.  Proteins as parameters in the discrimination between different blood-CSF barriers.

Authors:  G Keir; E J Thompson
Journal:  J Neurol Sci       Date:  1986-10       Impact factor: 3.181

4.  Intrathecal immunoglobulin M synthesis in multiple sclerosis. Relationship with clinical and cerebrospinal fluid parameters.

Authors:  M K Sharief; E J Thompson
Journal:  Brain       Date:  1991-02       Impact factor: 13.501

5.  Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions.

Authors:  K Selmaj; C S Raine; B Cannella; C F Brosnan
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

6.  A micro-method for measuring total protein in cerebrospinal fluid by using benzethonium chloride in microtiter plate wells.

Authors:  R W Luxton; P Patel; G Keir; E J Thompson
Journal:  Clin Chem       Date:  1989-08       Impact factor: 8.327

7.  A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone.

Authors:  F Barkhof; S T Frequin; O R Hommes; K Lamers; P Scheltens; W J van Geel; J Valk
Journal:  Neurology       Date:  1992-01       Impact factor: 9.910

8.  Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers.

Authors:  C P Hawkins; P M Munro; F MacKenzie; J Kesselring; P S Tofts; E P du Boulay; D N Landon; W I McDonald
Journal:  Brain       Date:  1990-04       Impact factor: 13.501

9.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis.

Authors:  A J Thompson; A G Kermode; D Wicks; D G MacManus; B E Kendall; D P Kingsley; W I McDonald
Journal:  Ann Neurol       Date:  1991-01       Impact factor: 10.422

Review 10.  The dissemination of multiple sclerosis. The Langdon-Brown lecture 1989.

Authors:  D A Compston
Journal:  J R Coll Physicians Lond       Date:  1990-07
View more
  6 in total

1.  Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  P J Jongen; K J Lamers; W H Doesburg; W A Lemmens; O R Hommes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

Review 2.  Cerebrospinal fluid.

Authors:  E J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-10       Impact factor: 10.154

3.  Evidence of persistent blood-brain barrier abnormalities in chronic-progressive multiple sclerosis.

Authors:  L Claudio; C S Raine; C F Brosnan
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

4.  Predictors for Therapy Response to Intrathecal Corticosteroid Therapy in Multiple Sclerosis.

Authors:  Katja Vohl; Alexander Duscha; Barbara Gisevius; Johannes Kaisler; Ralf Gold; Aiden Haghikia
Journal:  Front Neurol       Date:  2019-02-22       Impact factor: 4.003

Review 5.  Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis.

Authors:  C F Lucchinetti; W Brück; M Rodriguez; H Lassmann
Journal:  Brain Pathol       Date:  1996-07       Impact factor: 6.508

6.  Diagnostic Cerebrospinal Fluid Biomarker in Early and Late Onset Multiple Sclerosis.

Authors:  Franz Felix Konen; Malte Johannes Hannich; Philipp Schwenkenbecher; Matthias Grothe; Konrad Gag; Konstantin Fritz Jendretzky; Stefan Gingele; Kurt-Wolfram Sühs; Torsten Witte; Thomas Skripuletz; Marie Süße
Journal:  Biomedicines       Date:  2022-07-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.